ReviewCureus2025
Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zhaqu compound improves glucose and lipid metabolism in T2DM with MASLD by modulating gut microbiota and PPARγ.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a slowly progressive liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Despite multiple therapeutic approaches under investigation, no globally approved standard pharmacotherapy currently exists. This systematic review aims to inform and enhance critical care and hepatology practice by synthesizing the most recent evidence on the pathogenesis and treatment of MASH and associated fibrosis. The review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was performed using both text words and controlled vocabulary, incorporating Boolean operators ("AND," "OR") across PubMed, Embase, and the Cochrane Library. The inclusion criteria encompassed open-access, full-text English-language randomized controlled trials (RCTs) published between 2014 and 2024. Study quality was assessed using the RoB 2.0 tool, and the strength of evidence was evaluated using the GRADE framework. Fourteen RCTs were included. Of these, two were rated as high risk of bias (RoB) and consequently downgraded to "low-quality" evidence. Two RCTs with low RoB were classified as "high-quality" evidence, while the remaining 10 trials had unclear RoB, leading to a "moderate-quality" rating due to imprecision. This review discusses clinical trials evaluating therapies such as GLP-1 receptor agonists, THR-β agonists, pan-PPAR agonists, FGF21 analogues, and bariatric surgery. GLP-1 agonists and resmetirom (a THR-β agonist) demonstrated substantial reductions in liver fat content, while lanifibranor (a pan-PPAR agonist) also significantly improved fibrosis. Bariatric surgery showed MASH resolution in 56-70% of cases, though challenges remain regarding incomplete fibrosis reversal and the lack of long-term outcome data. Future research should prioritize combination therapies, explore novel antifibrotic agents, and investigate genetically based therapeutic strategies to better address the multifactorial nature of MASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.